Skip to content
Linkedin
Search
Drug Approvals
Regulatory News
Trial Results
Trial Status
Business News
Conference Coverage
About Us
Drug Approvals
Regulatory News
Trial Results
Trial Status
Business News
Conference Coverage
About Us
Choose Speciality
Close Choose Speciality
Open Choose Speciality
Post content
Brain Cancer
Breast Cancer
HER2+ HRneg Breast Cancer
HR+ HER2neg Breast Cancer
TNBC
GI Cancers
Cholangiocarcinoma
Colorectal Cancer
Esophageal Cancer
Gastric Cancer
GEJ
GIST
HCC
Pancreatic Cancer
GU Cancers
Bladder Cancer
Prostate Cancer
Renal Cell Carcinoma
Gynecological Cancers
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Head & Neck Cancer
Nasopharyngeal Carcinoma
Oropharyngeal Cancer
Hematological Malignancies
Bone Marrow & Stem Cell Transplant
CAR-Ts
Leukemias
ALL
AML
Chronic Myeloid Leukemia
CLL/SLL
CMML
Lung Cancer
Biomarker-Driven Lung Cancer
EGFR+ Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Lymphomas
DLBCL
Follicular Lymphoma
Hodgkin’s Lymphoma
Mantle Cell Lymphoma
Non-Hodgkin’s Lymphoma
T-Cell Lymphoma
MPNs
Multiple Myeloma
Myelodysplastic Syndromes
Neuroendocrine Tumors
Sarcoma
Skin Cancer
Solid Tumors
Targeted Therapy
Thyroid Cancer
Uveal Melanoma
Drug Approvals
Regulatory News
Trial Results
Trial Status
Business News
Conference Coverage
About Us
Drug Approvals
Regulatory News
Trial Results
Trial Status
Business News
Conference Coverage
About Us
Choose Speciality
Close Choose Speciality
Open Choose Speciality
Post content
Brain Cancer
Breast Cancer
HER2+ HRneg Breast Cancer
HR+ HER2neg Breast Cancer
TNBC
GI Cancers
Cholangiocarcinoma
Colorectal Cancer
Esophageal Cancer
Gastric Cancer
GEJ
GIST
HCC
Pancreatic Cancer
GU Cancers
Bladder Cancer
Prostate Cancer
Renal Cell Carcinoma
Gynecological Cancers
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Head & Neck Cancer
Nasopharyngeal Carcinoma
Oropharyngeal Cancer
Hematological Malignancies
Bone Marrow & Stem Cell Transplant
CAR-Ts
Leukemias
ALL
AML
Chronic Myeloid Leukemia
CLL/SLL
CMML
Lung Cancer
Biomarker-Driven Lung Cancer
EGFR+ Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Lymphomas
DLBCL
Follicular Lymphoma
Hodgkin’s Lymphoma
Mantle Cell Lymphoma
Non-Hodgkin’s Lymphoma
T-Cell Lymphoma
MPNs
Multiple Myeloma
Myelodysplastic Syndromes
Neuroendocrine Tumors
Sarcoma
Skin Cancer
Solid Tumors
Targeted Therapy
Thyroid Cancer
Uveal Melanoma
Linkedin
Search
TOP STORIES from the week
NDA Submission Completed for Zipalertinib + Chemo in 1L EGFR Exon 20 Ins Mutation NSCLC
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
Updated Glioblastoma Data Demonstrated Median OS of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
FDA Fast Track Designation for Onvansertib in 1L RAS-Mutated Metastatic CRC
Faeth Therapeutics and Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
European Commission approves TECVAYLI (teclistamab) monotherapy for relapsed/refractory multiple myeloma
October 27, 2026
FDA Fast Track Designation for Onvansertib in 1L RAS-Mutated Metastatic CRC
November 18, 2026
PIVOT-006 Ph 3 Registrational Trial shows RFS Improvement in Intermediate-Risk and High-Grade Ta NMIBC
November 18, 2026
First Patient dosed in Ph 3 RASolve 308 Trial of Zoldonrasib + Pembrolizumab and Chemo in 1L Metastatic RAS G12D Non-Squamous NSCLC
October 28, 2026
Faeth Therapeutics and Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
November 18, 2026
Stay up to date with OTW
Get all oncology clinical development news in your inbox
Please leave this field empty
Check your inbox or spam folder to confirm your subscription.
Drug approvals
Perioperative Imfinzi approved in the US in novel regimen with neoadjuvant enfortumab vedotin for patients with MIBC
November 18, 2026
FDA approves Wilserdly (giredestrant) for ER-positive, ESR1-mutated advanced breast cancer
November 18, 2026
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
November 4, 2026
FDA approves TALZENNA plus XTANDI for HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer
October 28, 2026
Regulatory news
NDA Submission Completed for Zipalertinib + Chemo in 1L EGFR Exon 20 Ins Mutation NSCLC
November 18, 2026
FDA Fast Track Designation for Onvansertib in 1L RAS-Mutated Metastatic CRC
November 18, 2026
CRL Received from FDA for BLA Application Based on HARMONi Study of ivonescimab + platinum-containing chemo for EGFR TKI-treated NSCLC patients
November 18, 2026
Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for ccRCC Following Treatment With an Anti-PD-1/PD-L1 Therapy
November 18, 2026
Trial results
Updated Glioblastoma Data Demonstrated Median OS of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
November 18, 2026
PIVOT-006 Ph 3 Registrational Trial shows RFS Improvement in Intermediate-Risk and High-Grade Ta NMIBC
November 18, 2026
68% high-grade RFS reported at 12 months in BCG-unresponsive NMIBC study of HIVEC® with mitomycin C
November 18, 2026
Positive Preliminary Ph 2 Topline Results Reported from the PIK-201 Trial of PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
November 18, 2026
trial status
First Patient dosed in Ph 1 Clinical Trial of VIPER-101
November 18, 2026
BLA Submission for Detalimogene to be initiated by Year End based on New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC patients
November 18, 2026
First Patient Dosed in OVACT Ph 1/1b Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer
November 11, 2026
Ph 1/2 Study of Vopimetostat in Combination with ERAS-0015 Initiated in patients with MTAP-deleted pancreatic cancer and MTAP-deleted/RAS mutant NSCLC
November 11, 2026
Business news
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
November 18, 2026
Faeth Therapeutics and Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
November 18, 2026
Natera Announces Clinical Collaboration with Incyte on Interventional Ph 2 Study in CRC
November 18, 2026
Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis
November 18, 2026
Archive
2025
2024
2023
2022
2021
2020
2019
2018